Neumora Therapeutics is trading 5.7% down at $0.65; the reason for the September 29, 2026 decline remains unclear.
- The investor-relations page lists August 14 as the latest release, with no new announcement for this session.
- Major U.S. indices were also lower, but reported declines were modest; available evidence does not establish broad-market weakness as the cause.